368 related articles for article (PubMed ID: 30500440)
1. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
[TBL] [Abstract][Full Text] [Related]
2. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
[TBL] [Abstract][Full Text] [Related]
3. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
4. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
DeZern AE; Eapen M; Wu J; Talano JA; Solh M; Dávila Saldaña BJ; Karanes C; Horwitz ME; Mallhi K; Arai S; Farhadfar N; Hexner E; Westervelt P; Antin JH; Deeg HJ; Leifer E; Brodsky RA; Logan BR; Horowitz MM; Jones RJ; Pulsipher MA
Lancet Haematol; 2022 Sep; 9(9):e660-e669. PubMed ID: 35907408
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
Klein OR; Buddenbaum J; Tucker N; Chen AR; Gamper CJ; Loeb D; Zambidis E; Llosa NJ; Huo JS; Robey N; Holuba MJ; Kasamon YL; McCurdy SR; Ambinder R; Bolaños-Meade J; Luznik L; Fuchs EJ; Jones RJ; Cooke KR; Symons HJ
Biol Blood Marrow Transplant; 2017 Feb; 23(2):325-332. PubMed ID: 27888014
[TBL] [Abstract][Full Text] [Related]
7. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
[TBL] [Abstract][Full Text] [Related]
8. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.
Bolaños-Meade J; Fuchs EJ; Luznik L; Lanzkron SM; Gamper CJ; Jones RJ; Brodsky RA
Blood; 2012 Nov; 120(22):4285-91. PubMed ID: 22955919
[TBL] [Abstract][Full Text] [Related]
9. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
[TBL] [Abstract][Full Text] [Related]
10. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
11. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
[TBL] [Abstract][Full Text] [Related]
12. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
[TBL] [Abstract][Full Text] [Related]
13. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
14. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
15. Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post-transplant cytoxan for sickle cell disease.
Patel DA; Dhedin N; Chen H; Karnik L; Gatwood K; Culos K; Mohan S; Engelhardt BG; Kitko C; Connelly J; Satyanarayana G; Jagasia M; De La Fuente J; Kassim A
Transpl Infect Dis; 2020 Feb; 22(1):e13222. PubMed ID: 31782875
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
Munchel AT; Kasamon YL; Fuchs EJ
Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
[TBL] [Abstract][Full Text] [Related]
18. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.
O'Donnell PV; Luznik L; Jones RJ; Vogelsang GB; Leffell MS; Phelps M; Rhubart P; Cowan K; Piantados S; Fuchs EJ
Biol Blood Marrow Transplant; 2002; 8(7):377-86. PubMed ID: 12171484
[TBL] [Abstract][Full Text] [Related]
20. Haploidentical bone marrow transplants for haematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
Bilmon IA; Kwan J; Gottlieb D; Kerridge I; McGurgan M; Huang G; George B; Hertzberg M; Bradstock KF
Intern Med J; 2013 Feb; 43(2):191-6. PubMed ID: 22646924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
